182 related articles for article (PubMed ID: 7726503)
1. Activity of carbapenem BMS-181139 against Pseudomonas aeruginosa is not dependent on porin protein D2.
Fung-Tomc JC; Gradelski E; Kolek B; Minassian B; Pucci M; Kessler RE; Bonner DP
Antimicrob Agents Chemother; 1995 Feb; 39(2):386-93. PubMed ID: 7726503
[TBL] [Abstract][Full Text] [Related]
2. Structure-activity relationships of carbapenems that determine their dependence on porin protein D2 for activity against Pseudomonas aeruginosa.
Fung-Tomc JC; Huczko E; Banville J; Ménard M; Kolek B; Gradelski E; Kessler RE; Bonner DP
Antimicrob Agents Chemother; 1995 Feb; 39(2):394-9. PubMed ID: 7726504
[TBL] [Abstract][Full Text] [Related]
3. Biochemical characterization of novel tetrahydrofuranyl 1beta-methylcarbapenems: stability to hydrolysis by renal dehydropeptidases and bacterial beta-lactamases, binding to penicillin binding proteins, and permeability properties.
Yang Y; Testa RT; Bhachech N; Rasmussen BA; Bush K
Antimicrob Agents Chemother; 1999 Dec; 43(12):2904-9. PubMed ID: 10582880
[TBL] [Abstract][Full Text] [Related]
4. Biochemical comparison of imipenem, meropenem and biapenem: permeability, binding to penicillin-binding proteins, and stability to hydrolysis by beta-lactamases.
Yang Y; Bhachech N; Bush K
J Antimicrob Chemother; 1995 Jan; 35(1):75-84. PubMed ID: 7768785
[TBL] [Abstract][Full Text] [Related]
5. In-vitro activity of biapenem, compared with imipenem and meropenem, against Pseudomonas aeruginosa strains and mutants with known resistance mechanisms.
Chen HY; Livermore DM
J Antimicrob Chemother; 1994 May; 33(5):949-58. PubMed ID: 8089068
[TBL] [Abstract][Full Text] [Related]
6. Affinities of BO-2727 for bacterial penicillin-binding proteins and morphological change of gram-negative rods.
Hashizume T; Nakamura K; Nakagawa S
J Antibiot (Tokyo); 1997 Feb; 50(2):139-42. PubMed ID: 9099223
[TBL] [Abstract][Full Text] [Related]
7. Antibacterial activity of meropenem against gram-negative bacteria with a permeability defect and against staphylococci.
Kitzis MD; Acar JF; Gutmann L
J Antimicrob Chemother; 1989 Sep; 24 Suppl A():125-32. PubMed ID: 2808204
[TBL] [Abstract][Full Text] [Related]
8. Potent activity of meropenem against Escherichia coli arising from its simultaneous binding to penicillin-binding proteins 2 and 3.
Sumita Y; Fukasawa M
J Antimicrob Chemother; 1995 Jul; 36(1):53-64. PubMed ID: 8537284
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of enhanced antipseudomonal activity of BO-2727, a new injectable 1-beta-methyl carbapenem.
Hazumi N; Fuse A; Matsuda K; Hashizume T; Sanada M
Antimicrob Agents Chemother; 1995 Mar; 39(3):702-6. PubMed ID: 7793876
[TBL] [Abstract][Full Text] [Related]
10. Diffusion of meropenem and imipenem through the outer membrane of Escherichia coli K-12 and correlation with their antibacterial activities.
Cornaglia G; Guan L; Fontana R; Satta G
Antimicrob Agents Chemother; 1992 Sep; 36(9):1902-8. PubMed ID: 1416880
[TBL] [Abstract][Full Text] [Related]
11. Antimicrobial activity of SM-17466, a novel carbapenem antibiotic with potent activity against methicillin-resistant Staphylococcus aureus.
Sumita Y; Nouda H; Kanazawa K; Fukasawa M
Antimicrob Agents Chemother; 1995 Apr; 39(4):910-6. PubMed ID: 7785994
[TBL] [Abstract][Full Text] [Related]
12. Emergence of resistance to beta-lactam antibiotics in Pseudomonas aeruginosa during treatment with new beta-lactams.
Lerner SA; Quinn JP
Chemioterapia; 1985 Feb; 4(1):95-101. PubMed ID: 3921267
[TBL] [Abstract][Full Text] [Related]
13. Structure-activity relationships of carbapenem compounds to anti-Haemophilus influenzae activity and affinity for penicillin-binding proteins. Effect of 1 beta-methyl group and C-2 side chain.
Kanazawa K; Nouda H; Sunagawa M
J Antibiot (Tokyo); 1997 Feb; 50(2):162-8. PubMed ID: 9099227
[TBL] [Abstract][Full Text] [Related]
14. Comparison of two carbapenems, SM-7338 and imipenem: affinities for penicillin-binding proteins and morphological changes.
Sumita Y; Fukasawa M; Okuda T
J Antibiot (Tokyo); 1990 Mar; 43(3):314-20. PubMed ID: 2108953
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo evaluation of BO-2727 against imipenem- and/or meropenem-resistant Pseudomonas aeruginosa.
Shibata K; Adachi Y; Kato E; Nagano R; Fuse A; Hashizume T; Ohtake N; Okamoto O; Nakagawa S
J Antibiot (Tokyo); 1997 Feb; 50(2):135-8. PubMed ID: 9099222
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of BMS-181139, a new carbapenem with potent antipseudomonal activity.
Kessler RE; Fung-Tomc J; Kolek B; Minassian B; Huczko E; Gradelski E; Bonner DP
Antimicrob Agents Chemother; 1995 Feb; 39(2):380-5. PubMed ID: 7726502
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of imipenem resistance acquired by three Pseudomonas aeruginosa strains during imipenem therapy.
Vurma-Rapp U; Kayser FH; Hadorn K; Wiederkehr F
Eur J Clin Microbiol Infect Dis; 1990 Aug; 9(8):580-7. PubMed ID: 2120059
[TBL] [Abstract][Full Text] [Related]
18. [Carbapenem antibiotics].
Watanabe A
Nihon Rinsho; 2003 Feb; 61 Suppl 2():737-43. PubMed ID: 12722309
[No Abstract] [Full Text] [Related]
19. In vitro activity of LJC10,627, a new carbapenem antibiotic with high stability to dehydropeptidase I.
Ubukata K; Hikida M; Yoshida M; Nishiki K; Furukawa Y; Tashiro K; Konno M; Mitsuhashi S
Antimicrob Agents Chemother; 1990 Jun; 34(6):994-1000. PubMed ID: 2203313
[TBL] [Abstract][Full Text] [Related]
20. Bacterial resistance to carbapenems.
Livermore DM
Adv Exp Med Biol; 1995; 390():25-47. PubMed ID: 8718600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
